Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study

Objectives: To study possible psychopathological symptoms and cognitive deficits, abuse induction, as well as general tolerability and effects on quality of life, fatigue and motor function in cannabis-naïve patients with multiple sclerosis (MS) treated with a free-dose cannabis plant extract (Sativex). Methods: In an 8-week, randomized, double-blind, placebo-controlled, parallel group crossover trial, 17 cannabis-naïve patients with MS were assessed at baseline and at the end of the cannabis and placebo phases of the trial (each of 3 weeks) by means of Symptom Checklist-90 Revised, Self-rating Anxiety Scale, Multiple Sclerosis Functional Composite (of which 1 dimension is the Paced Auditory Serial Additional Test that was used to evaluate cognition), Visual Analogue Scale on health-related quality of life, Multiple Sclerosis Impact Scale-29, and Fatigue Severity Scale. Results: Postplacebo versus postcannabinoid scores showed that no significant differences could be detected on all the variables under study. A significant positive correlation was found between &Dgr;-9-tetrahydrocannabinol blood levels and scores at the General Symptomatic Index and at the "interpersonal sensitivity," "aggressive behaviour," and "paranoiac tendencies" subscales of the Symptom Checklist-90 Revised. No serious adverse events, abuse tendencies, or direct withdrawal symptoms were reported. Increased desire for Sativex with secondary depression was reported in 1 subject. Conclusions: Cannabinoid treatment did not induce psychopathology and did not impair cognition in cannabis-naïve patients with MS. However, the positive correlation between blood levels of &Dgr;-9-tetrahydrocannabinol and psychopathological scores suggests that at dosages higher than those used in therapeutic settings, interpersonal sensitivity, aggressiveness, and paranoiac features might arise, although greater statistical power would be necessary to confirm this finding.

[1]  P. Munk-Jørgensen,et al.  Testing the self-medication hypothesis of depression and aggression in cannabis dependent subjects , 2007, European Psychiatry.

[2]  C. Collin,et al.  Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis , 2007, European journal of neurology.

[3]  C. Hart,et al.  Neuropsychological deficits in long-term frequent cannabis users , 2006, Neurology.

[4]  K. Koivisto,et al.  The PASAT performance among patients with multiple sclerosis: analyses of responding patterns using different scoring methods , 2006, Multiple sclerosis.

[5]  D. Wade,et al.  Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis , 2006, Multiple sclerosis.

[6]  G. Simon,et al.  Outcome of new benzodiazepine prescriptions to older adults in primary care. , 2006, General hospital psychiatry.

[7]  C. Tanton,et al.  Cannabis use in patients with multiple sclerosis , 2006, Multiple sclerosis.

[8]  L. Degenhardt,et al.  Is Cannabis Use a Contributory Cause of Psychosis? , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[9]  N. Ramsey,et al.  Long-term effects of frequent cannabis use on working memory and attention: an fMRI study , 2006, Psychopharmacology.

[10]  B. Uitdehaag,et al.  Cannabinoids in multiple sclerosis: urgent need for long term trials , 2005, Journal of Neurology Neurosurgery & Psychiatry.

[11]  A. Thompson,et al.  Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  David Kavanagh,et al.  Cannabis use and misuse prevalence among people with psychosis. , 2005, The British journal of psychiatry : the journal of mental science.

[13]  T. Friede,et al.  Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis , 2005, Neurology.

[14]  S. Lawrie,et al.  Cannabis as a risk factor for psychosis: systematic review , 2005, Journal of psychopharmacology.

[15]  L. Iversen.  Long-term effects of exposure to cannabis. , 2005, Current opinion in pharmacology.

[16]  J. Os,et al.  Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people , 2004, BMJ : British Medical Journal.

[17]  J. Os,et al.  Early adolescent cannabis exposure and positive and negative dimensions of psychosis. , 2004, Addiction.

[18]  C. Vaney,et al.  Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study , 2004, Multiple sclerosis.

[19]  T. Jensen,et al.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial , 2004, BMJ : British Medical Journal.

[20]  Nigel Rice,et al.  Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life. , 2004, Social science & medicine.

[21]  Ralitza Gueorguieva,et al.  The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis , 2004, Neuropsychopharmacology.

[22]  A. Stinchcomb,et al.  Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[23]  P. Dannon,et al.  Comorbid cannabis use and panic disorder: short term and long term follow‐up study , 2004, Human psychopharmacology.

[24]  M. Pérez-García,et al.  Clinical Implications and Methodological Challenges in the Study of the Neuropsychological Correlates of Cannabis, Stimulant, and Opioid Abuse , 2004, Neuropsychology Review.

[25]  S. Ventegodt,,et al.  Psychoactive Drugs and Quality of Life , 2003, TheScientificWorldJournal.

[26]  Vincent A Magnotta,et al.  Marijuana alters the human cerebellar clock , 2003, Neuroreport.

[27]  Ethan B. Russo.  Safety, tolerability, and efficacy of orally administered cannabinoids in MS , 2003, Neurology.

[28]  J. Larsen,et al.  Measuring fatigue in patients with Parkinson's disease – the Fatigue Severity Scale , 2002, European journal of neurology.

[29]  C. Brignell,et al.  Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users , 2002, Psychopharmacology.

[30]  R. Bonnel,et al.  Abuse, dependence, or withdrawal associated with tramadol. , 2002, The American journal of psychiatry.

[31]  Thomas Babor,et al.  Cognitive functioning of long-term heavy cannabis users seeking treatment. , 2002, JAMA.

[32]  A Thompson,et al.  The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. , 2001, Brain : a journal of neurology.

[33]  M. Aragona,et al.  Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. , 2000, Clinical neuropharmacology.

[34]  S. Reingold,et al.  The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.

[35]  H Thomas,et al.  A community survey of adverse effects of cannabis use. , 1996, Drug and alcohol dependence.

[36]  S. Marriott,et al.  Benzodiazepine Dependence , 1993, Drug safety.

[37]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[38]  W W Zung,et al.  A rating instrument for anxiety disorders. , 1971, Psychosomatics.

[39]  Tom T Bogt,et al.  Cannabis use andmental health in secondary school children Findings from a Dutch survey , 2005 .

[40]  J. Rein,et al.  The perceived effects of smoked cannabis on patients with multiple sclerosis. , 1997, European neurology.

[41]  Lr Derogatis,et al.  SCL-90-R, Administration, Scoring, and Procedures Manual-II for the R(evised) Version and Other Instruments of the Psychopathology Rating Scale Series , 1983 .